BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 30939962)

  • 1. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
    Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
    J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
    [No Abstract]   [Full Text] [Related]  

  • 2. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients.
    Annemans L; Moeremans K; Lamotte M; Garcia Conde J; van den Berg H; Myint H; Pieters R; Uyttebroeck A
    Support Care Cancer; 2003 Apr; 11(4):249-57. PubMed ID: 12673464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
    Knoebel RW; Lo M; Crank CW
    J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
    Kennedy LD; Ajiboye VO
    J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
    Jeon YW; Kwak DH; Park SS; Yoon JH; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Min WS; Cho SG
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):595-603. PubMed ID: 28711571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey.
    Bertrand Y; Mechinaud F; Brethon B; Mialou V; Auvrignon A; Nelken B; Notz-Carrère A; Plantaz D; Patte C; Urbieta M; Baruchel A; Leverger G;
    J Pediatr Hematol Oncol; 2008 Apr; 30(4):267-71. PubMed ID: 18391694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report.
    Galardy PJ; Hochberg J; Perkins SL; Harrison L; Goldman S; Cairo MS
    Br J Haematol; 2013 Nov; 163(3):365-72. PubMed ID: 24032600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose rasburicase in hematologic malignancies.
    Jayabose S; Kumar V; Dhanabalan R; Rajan P; Rathnam K; Viswanathan TK
    Indian J Pediatr; 2015 May; 82(5):458-61. PubMed ID: 25338496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rasburicase for the management of tumor lysis syndrome in neonates.
    McNutt DM; Holdsworth MT; Wong C; Hanrahan JD; Winter SS
    Ann Pharmacother; 2006; 40(7-8):1445-50. PubMed ID: 16868218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clarifying the role of rasburicase in tumor lysis syndrome.
    Sood AR; Burry LD; Cheng DK
    Pharmacotherapy; 2007 Jan; 27(1):111-21. PubMed ID: 17192165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome.
    Cairo MS; Thompson S; Tangirala K; Eaddy MT
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):173-178. PubMed ID: 27965022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic implications of rasburicase treatment in adult patients with tumour lysis syndrome.
    Eaddy M; Seal B; Tangirala K; Davies EH; O'Day K
    Appl Health Econ Health Policy; 2012 Nov; 10(6):431-40. PubMed ID: 23013428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-based management strategy and outcomes of tumor lysis syndrome in children with leukemia/lymphoma: Analysis from a resource-limited setting.
    Gopakumar KG; Seetharam S; Km JK; Nair M; Rajeswari B; Cs G; Vr P; Thankamony P
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27401. PubMed ID: 30101454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients.
    Eaddy M; Seal B; Tangirala M; Davies EH; O'Day K
    Am J Health Syst Pharm; 2010 Dec; 67(24):2110-4. PubMed ID: 21116002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
    Feng X; Dong K; Pham D; Pence S; Inciardi J; Bhutada NS
    J Clin Pharm Ther; 2013 Aug; 38(4):301-8. PubMed ID: 23550846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
    Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
    Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
    Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
    Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
    Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A
    Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rasburicase in the prevention and treatment of tumour lysis syndrome.
    Mayne N; Keady S; Thacker M
    Intensive Crit Care Nurs; 2008 Feb; 24(1):59-62. PubMed ID: 17698360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
    Gupta G; Seth T; Garg V; Juneja R; Mahapatra M; Datta SK; Upadhyay AD; Saxena R
    Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e99-e104. PubMed ID: 33039358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.